A:

In 1982,

The U.S. Food and Drug Administration (FDA) recognized the lack of incentive for pharmaceutical companies to develop cures for rare diseases and established the Office of Orphan Product Development. This branch of the FDA provides incentives to companies that work toward curing rare diseases by exercising the rights given to them under the Orphan Drug Act of January 1983. One type of incentive is the orphan drug status, which provides tax reductions and the exclusive right to develop the cure for a specific condition for a period of seven years to companies attempting to cure rare diseases.

Developing drugs to treat the vast number of diseases in the world is a line of business that can lead to massive fortunes, but unfortunately not all developed drugs become the golden ticket. In the world pharmaceuticals, the largest amount of money can be made by developing drugs that become the standard for curing common diseases.

From a business perspective, having a large market ensures that a company can quickly recuperate the cost of development and can also realize the largest possible gain. For this reason, there is little incentive for pharmaceutical companies to develop cures for rare diseases - those that affect fewer than 200,000 people in the United States - because the small market and high cost associated with finding these types of cures discourages these companies from entering this market.

For related reading, check out Measuring The Medicine Makers.

RELATED FAQS
  1. How does government regulation impact the drugs sector?

    Learn about how drugs are regulated by the U.S. government as well as the role of the Food and Drug Administration during ... Read Answer >>
  2. What are the primary risks associated with investing in the drugs sector?

    Learn more about the primary risks facing investors in the pharmaceutical and biotechnology industries. Find out how regulation ... Read Answer >>
  3. What is the drugs sector?

    Learn more about the drug industry and how new drugs are brought to market. Find out about how drug research is financed ... Read Answer >>
  4. What does it mean that an investor faces binary outcomes when investing in drug companies?

    Learn why investments in biotech and drug companies can result in what are called binary outcomes, and understand why these ... Read Answer >>
  5. What process does a company need to follow to bring a new drug to market?

    Learn about the costly price of bringing new drugs to market. Discover why the pharmaceutical industry invests billions of ... Read Answer >>
  6. What are the major barriers to entry for new companies in the drugs sector?

    Find out why barriers to entry for U.S. drug companies are so high and how the Food and Drug Administration, or FDA, inhibits ... Read Answer >>
Related Articles
  1. Investing

    Orphan Drug Rules Are Being Manipulated

    It may be the time to revamp the Orphan Drug Program amid concerns it's turning into a scam.
  2. Investing

    CURE: Direxion Daily Healthcare Bull 3X ETF

    Learn about the Direxion Daily Healthcare Bull. This is a leveraged ETF that tracks the health care sector, which is a leader in this bull market.
  3. Insights

    AstraZeneca's NMOSD Drug Gets EU Orphan Drug Status (AZN)

    AstraZeneca's Inebilizumab (MEDI-551) has secured orphan drug status in EU, making it eligible for several key benefits including market exclusivity
  4. Investing

    Alexion Blood Disorder Meds Wins Orphan Drug Status

    Alexion's blood-disorder drug has now received orphan drug status in both the US and the EU.
  5. Investing

    Evaluating Pharmaceutical Companies

    Learn how to find a healthy pharmaceutical investment in a market full of weak drugs.
  6. Investing

    A Primer On The Biotech Sector

    Investing in the biotech sector can involve both huge losses and major gains.
  7. Investing

    Opko Gets Orphan Status for Genetic Disorder Drug

    Opko’s neurological disorder drug CUR-1916 qualifies for many benefits under orphan drug status.
  8. Personal Finance

    Senate Passes Bill to Expedite Drug Approval

    The US Senate just passed the biggest health reform bill since Obamacare.
  9. Insights

    How Pharmaceutical Companies Price Their Drugs

    Learn more about how pharmaceutical companies price drugs, why prices are often very high and why it can be difficult to settle on a suitable price.
  10. Investing

    Moleculin Leukemia Drug Gets Orphan Drug Status

    Moleculin Biotech’s lead AML drug candidate Annamycin qualified for the FDA’s orphan drug status.
RELATED TERMS
  1. Orphan Drug Credit

    A federal tax credit that provides an incentive for pharmaceutical ...
  2. Drug

    A substance that cures, treats, prevents or reduces the symptoms ...
  3. New Drug

    A new medication or therapy that has not been used before in ...
  4. Food And Drug Administration - FDA

    A government agency established in 1906 with the passage of the ...
  5. Dread Disease Rider

    A special addition to a life insurance policy that gives a percentage ...
  6. Disease Management Program

    Disease management programs can help control health care expenses ...
Hot Definitions
  1. Market Capitalization

    The total dollar market value of all of a company's outstanding shares. Market capitalization is calculated by multiplying ...
  2. Expense Ratio

    A measure of what it costs an investment company to operate a mutual fund. An expense ratio is determined through an annual ...
  3. Mezzanine Financing

    A hybrid of debt and equity financing that is typically used to finance the expansion of existing companies. Mezzanine financing ...
  4. Long Run

    A period of time in which all factors of production and costs are variable. In the long run, firms are able to adjust all ...
  5. Quasi Contract

    A legal agreement created by the courts between two parties who did not have a previous obligation to each other. A normal ...
  6. Wage-Price Spiral

    A macroeconomic theory to explain the cause-and-effect relationship between rising wages and rising prices, or inflation. ...
Trading Center